Disclosed herein are compositions useful for the treatment and/or prevention of various diseases and conditions, including a variety of infections, via internal administration to a patient. The compositions comprise an effective amount of a halo active aromatic sulfonamide compound having the structure of Formula (I):

##STR00001##

wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5, X, and M are defined herein. The compositions described may be used to treat and/or prevent a variety of infections, including bacterial infections, viral infections, fungal infections, and the like. The compositions can be internally administered to a patient via at least one of: oral administration, pulmonary administration, subcutaneous administration, sublingual administration, ocular administration, otic administration, intravenous administration, inter-dermal administration, epidural administration, intraperitoneal administration, and intramuscular administration.

Compositions and methods for the diagnosis and treatment of lymphatic anomaly are disclosed.

A vascular adhesion protein-1 (VAP-1) inhibitor can be used as a regulator of reactive oxygen species (ROS) concentration in ex vivo culturing of hematopoietic stem cells, which enables a method of producing an expanded population of hematopoietic5 stem cells ex vivo. Further, a VAP-1 inhibitor can be used in the treatment of bone marrow suppression or bone barrow failure in an individual.

A vascular adhesion protein-1 (VAP-1) inhibitor can be used as a regulator of reactive oxygen species (ROS) concentration in ex vivo culturing of hematopoietic stem cells, which enables a method of producing an expanded population of hematopoietic5 stem cells ex vivo. Further, a VAP-1 inhibitor can be used in the treatment of bone marrow suppression or bone barrow failure in an individual.

Disclosed herein in is a method of increasing plasma dileucine levels in a subject comprising administering to the subject an effective amount of a composition comprising leucine. In certain embodiments, the composition does not comprise dileucine. In certain embodiments, the amount of increase in plasma dileucine is greater than that resulting from administering a protein supplement comprising a comparable amount of leucine. In certain implementations, administration of the composition results in an increase in plasma dileucine that is from about 10% to about 50% greater than from administering a protein supplement comprising a comparable amount of leucine.

The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.

The present disclosure provides compositions and methods for promoting stem cell and/or progenitor cell proliferation and/or differentiation. The provided compositions may be useful in treating a disease or condition that is related to mucosal barrier function, e.g., wound healing, treating skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, or condition related to the aging of skin), treating a lung disorders (e.g., asthma), a condition related to improving mucosal barrier function, and/or treating injury to GI mucosa in a subject in need thereof. The present disclosure also provides methods for promoting the proliferation and/or differentiation of stem cells and/or the progenitor cells in a subject in need of such treatment by administering a composition. The ability to stimulate the proliferation and/or differentiation of stem cells and/or the progenitor cells in vivo, ex vivo and/or in vitro provides tremendous benefit. The present disclosure can be used to increase stem cell populations in in vivo, ex vivo and/or in vitro. Stem cell transplantation provides treatments and/or cures of many disease states, degeneration and/or injury.

One aspect of the present disclosure relates to a functional food composition having a cranial nerve protective effect and a blood flow improvement effect and including antler, an Angelica gigas root, a Cornus officinalis fruit, a Rehmannia glutinosa root, Lepidium meyenii root powder, a hawthorn fruit, an Astragalus membranaceus root, a cod seed, aloeo wood, a Paeonia lactiflora root, a Cnidium officinale root stem and a Citrus reticulata shell.

One aspect of the present disclosure relates to a functional food composition having a cranial nerve protective effect and a blood flow improvement effect and including antler, an Angelica gigas root, a Cornus officinalis fruit, a Rehmannia glutinosa root, Lepidium meyenii root powder, a hawthorn fruit, an Astragalus membranaceus root, a cod seed, aloeo wood, a Paeonia lactiflora root, a Cnidium officinale root stem and a Citrus reticulata shell.

The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.